Your browser doesn't support javascript.
loading
177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy.
John, Nikeith; Pathmanandavel, Sarennya; Crumbaker, Megan; Counter, William; Ho, Bao; Yam, Andrew O; Wilson, Peter; Niman, Remy; Ayers, Maria; Poole, Aron; Hickey, Adam; Agrawal, Shikha; Perkins, Gary; Kallinen, Annukka; Eslick, Enid; Stockler, Martin R; Joshua, Anthony M; Nguyen, Andrew; Emmett, Louise.
Afiliación
  • John N; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Pathmanandavel S; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Crumbaker M; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Counter W; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Ho B; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Yam AO; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Wilson P; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Niman R; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Ayers M; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Poole A; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Hickey A; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Agrawal S; MIM Software, Inc., Cleveland, Ohio; and.
  • Perkins G; MIM Software, Inc., Cleveland, Ohio; and.
  • Kallinen A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Eslick E; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Stockler MR; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Joshua AM; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Nguyen A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Emmett L; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
J Nucl Med ; 64(3): 410-415, 2023 03.
Article en En | MEDLINE | ID: mdl-36215568
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antígeno Prostático Específico / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: J Nucl Med Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antígeno Prostático Específico / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: J Nucl Med Año: 2023 Tipo del documento: Article País de afiliación: Australia